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Background: There is evidence that oxidative stress plays an 
important role in auto- immune diseases, such as rheumatoid arthritis 
(RA). Despite the supporting evidence for a beneficial effect of 
antioxidants on clinical characteristics of RA, the right balance for 
optimal effectiveness of antioxidants is largely unknown. A study was 
designed to determine the potential beneficial effects of antioxidant 
intervention on clinical parameters of RA. 
Methods: Randomized clinical trial of 152 patients with 
positive rheumatoid factor (RF) and a Disease Activity Score (DAS 
28) higher than 3.2 were enrolled in the study. Patients 
were   divided into two groups (Group A and Group B) 
randomly and   group A received methotrexate and antioxidant 
vitamins (A, C and E in a fixed dose) and group B methotrexate 
only. They were followed up for three visits (baseline, 10th week and 
14th week). The intervention was stopped after 10 weeks and was 
followed by a ‘wash-out’ period of 4 weeks. At baseline, 
10th week and 14th week patient’s condition were assessed by means 
of DAS-28 score. P- Value less than <0.05 was considered significant. 
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Introduction 
 
Rheumatoid arthritis (RA) is a chronic, inflammatory disorder that may 
affect many tissues and organs, but principally attacks flexible synovial joints. 
The process involves an inflammatory response of the capsule around the joints 
synovium secondary to swelling (hyperplasia) of synovial cells, excess synovial 
fluid, and the development of fibrous tissue (pannus) in the synovium. The 
pathology of the disease process often leads to the destruction of articular 
cartilage and ankylosis (fusion) of the joints. RA can also produce diffuse 
inflammation in the lungs, membrane around the heart (pericardium), the 
membranes of the lung (pleura), and white of the eye (sclera), and also nodular 
lesions, most common in subcutaneous tissue. Although the cause of RA is 
unknown, autoimmunity plays a pivotal role in both its chronicity and 
progression, and RA is considered a systemic autoimmune disease. The diagnosis 
of RA, particularly early in the course of disease is empirical and imprecise. 
Treatment of RA may be efficient if starts early. At the same time an early and 
accurate diagnosis may protect the patients who do not have RA, from aggressive 
therapies with potential toxicity [1].  
About 1% of the world's population is affected by RA, women three times 
more often than men. Onset is most frequent between the ages of 40 and 50, but 
people of any age can be affected. In addition, individuals with the HLA-DR1 or 
HLA-DR4 serotypes have an increased risk for developing the disorder. It can be 
a disabling and painful condition, which can lead to substantial loss of 
functioning and mobility if not adequately treated. It is a clinical diagnosis made 
on the basis of symptoms, physical examination, radiographs (X-rays) and 
laboratory findings, although the American College of Rheumatology (ACR) and 
the European League against Rheumatism (EULAR) published classification 
criteria for the purpose of research. Diagnosis and long-term management are 
Results: The numbers of swollen and tender joints were significantly 
reduced and general health was improved reflected by improved DAS-
28 score at 10th week. 
The antioxidant effect was considered beneficial as compared to the 
scores of 1st visit at base line; the DAS-28 score was significantly 
reduced at 2nd visit at 10th week. Increment of the DAS-28 score 
among the group A patients who were on antioxidant up to10 
weeks, after the “wash-out period” of four weeks i.e. at 14th week 
confirmed a significant relation between changes in clinical condition 
and antioxidants. 
Conclusion: This study was designed to assess the potential 
beneficial effect of antioxidants (Vitamin A, C and E) in combination 
with methotrexate in the treatment of RA. 
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typically performed by a rheumatologist, an expert in joint, muscle and bone 
diseases [1].  
 
The main aim of management of RA is to: 
• beneficially modify the disease process 
• educate the patient 
• control pain 
• optimize function  
 
These aims are interrelated and success in one area often benefits the others. 
Successful management inevitably requires careful assessment of the person as 
well as his or her musculo-skeletal system. The management plan needs to be 
individualized according to:  
• the person’s daily activity requirements and recreational aspirations 
• the person’s perceptions and knowledge of his/ her condition 
• medications and coping strategies already tried by the patient 
• co-morbid disease and it’s therapy 
• risk factors and associations of the musculoskeletal conditions 
 
The wide variety of treatment approaches may require the expertise of a 
number of health professionals, necessitating a coordinated multidisciplinary team 
approach for some patients [2]. Pharmacotherapy for RA generally involves 
NSAIDs for control of pain, with selective use of low-dose oral or intra-articular 
glucocorticoids, and initiation of a DMARD (Disease Modifying Anti-Rheumatic 
Drugs) [3]. In past decades, pharmacologic treatment of RA was managed using a 
pyramid approach, symptoms alleviating treatment were started at diagnosis, and 
only with progression of symptoms dosages were changed or additional 
medications added. However, a “reverse pyramid” approach now is favored, in 
which DMARDs are initiated quickly to slow disease progression as early as 
possible. This change of approach is a result of several research findings: (1) joint 
damage begins early in the disease; (2) DMARDs have significant benefits when 
used early; (3) the benefits of DMARDs may be enhanced when the drugs are 
used in combination (4) a number of new DMARDs are available, with good 
evidence of beneficial effect. Patients with mild disease and normal radiographic 
findings can begin treatment with hydroxychloroquine, sulfasalazine or 
minocycline, although methotrexate also is an option. Patients with more severe 
disease or radiographic changes should begin treatment with methotrexate. If 
symptoms are not adequately controlled, leflunomide, azathioprine or 
combination therapy (methotrexate plus one of the newer agents) may be 
considered. 
Antioxidant supplements and diets have long been advocated for the 
treatment of RA, osteoarthritis (OA) and other inflammatory arthritis [4]. 
However, the value of antioxidants in the prevention and treatment of a wide 
range of serious diseases including stroke, cancer, diabetes, cataracts, Parkinson's 
disease, Alzheimer's disease and arthritis has been questioned in the light of more 
recent negative research findings and studies suggesting that antioxidant 
properties may be absent or reduced in vivo, may only be important in those 
with a deficiency [4]. It therefore seems timely to assess the clinical evidence 
supporting the use of antioxidants specifically in arthritis. If shown to be safe and 
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effective, antioxidants may be an alternative to treatment with non-steroidal 
anti-inflammatory drugs (NSAIDs) or other drugs that are associated with 
adverse effects during long-term use.  
In RA, reactive oxygen species and other free radicals are associated with the 
inflammatory process via numerous pathways [5]. These include the role of 
nitrous oxide in regulating vascular tone, superoxide in fibroblast proliferation 
and hydrogen peroxide in the transcription of cytokines IL-2 and TNF-α. During 
inflammation, oxidation modifies low-density lipoproteins, inactivates α-1-
protease inhibitor, damages DNA and causes lipid peroxidation [5]. Reactive 
oxygen species also damage cartilage and the extracellular matrix and inhibit 
collagen and proteoglycan synthesis [6]. Evidence that increased oxidative stress 
or deficient antioxidant status are important in the pathogenesis of RA comes 
from several studies. Epidemiological studies have shown that low intake of 
dietary antioxidants is associated with the incidence of RA [4]. Furthermore, 
animal studies have demonstrated an anti-inflammatory role for some 
antioxidants including superoxide dismutase (SOD) and vitamin E in 
experimentally induced arthritis. Numerous clinical studies testing the 
effectiveness of specific antioxidants or particular antioxidant diets in the 
treatment of arthritis have been published during the last 30 yrs. Here, the study 
was designed for evaluation the effectiveness of the antioxidant vitamins A, C 
and E and methotrexate in comparison with methotrexate alone in the treatment 
of RA. 
 
 
Materials and methods 
 
A randomized open clinical trial held on department of Medicine, Chittagong 
Medical College Hospital, Chittagong, Bangladesh from July 2012 to January 
2014. All patients of both sexes between 16-70 years who were diagnosed as RA 
(ARA 2010) were enrolled in this study. Inclusion criteria are diagnosed case of 
RA by ACR/EULAR (2010) Classification Criteria, age at entry 16-70 years and 
DAS-28* score > 3.2 (i.e. moderate to very active diseases). Exclusion Criteria 
were patient having any arthritis other than RA, patients having contraindication 
to use methotrexate and antioxidant drugs (e.g. liver disease, renal disease, active 
tuberculosis and neoplastic diseases, etc), patients receiving antioxidants 
(Vitamin-A, C & E) more than three months before the study, patients on 
steroid therapy for more than three months before the study, pregnant and 
lactating women. 
 
Classification criteria of RA 7  
(2010 ACR-EULAR criteria) 
ACR: American College of Rheumatology, EULAR: European League against Rheumatism 
Score 
 1 large joint (shoulder, elbow, hip, knee, ankle) 0 
2–10 large joints 1 
1–3 small joints (MCP, PIP, Thumb IP, MTP, wrists) 2 
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Classification criteria of RA 7  
(2010 ACR-EULAR criteria) 
ACR: American College of Rheumatology, EULAR: European League against Rheumatism 
Score 
 
Joint involvement 
4–10 small joints 3 
>10 joints (at least 1 small joint) 5 
 
Serology 
Negative RF and negative ACPA 0 
Low-positive RF or low-positive anti-CCP antibodies (<3 times ULN) 2 
High-positive RF or high-positive anti-CCP antibodies (>3 times ULN) 3 
Acute-phase reactants Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
Duration of symptoms  <6 weeks 0 
>6 weeks 1 
 
The progression of RA can be followed using scores such as DAS-28. The 
joints included in DAS-28 score were (bilaterally): proximal interphalangeal 
joints (10 joints), meta- carpophalangeal joints (10), wrists (2), elbows (2), 
shoulders (2) and knees (2). When looking at these joints, both the number of 
joints with tenderness upon touching (TEN-28) and swelling (SW-28) were 
counted.  
In addition, the ESR was measured. Also, the patient makes a subjective 
assessment (SA) of disease activity during the preceding 7 days on a scale 
between 0 and 100, where 0 was “no activity" and 100 was “highest activity 
possible". With these parameters, DAS 28 score was calculated as: 
 
 
 
From this, the disease activity of the patient can be classified as follows [5]: 
 
 Current DAS 28 
score ≤ 3.2   >3.2 but ≤ 5.1 > 5.1 
DAS 28 score 
decreases from 
initial value 
 Inactive Moderate Very active 
> 1.2 Good improvement Moderate improvement 
Moderate  
improvement 
> 0.6 but ≤ 1.2 
Moderate 
improvement 
Moderate 
improvement No improvement 
≤ 0.6 No improvement No improvement No improvement 
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Procedure of the study 
 
 Total 152 patients of RA were selected for the study. All patients were 
informed about the treatment options. Written informed consent was taken from 
the patients. Ethical permission was also obtained from ethical review committee. 
Among the 152 patients 124 were finally selected who have DAS-28 score more 
than 3.2 (i.e. moderate to very active disease). Patients were divided in two 
groups (A&B) according to lottery and documentation of Case Record Form were 
done. Group A patients were given methotrexate (Batch no. 72E97044, Mfg 
Date. Aug 2011, Delta Pharmaceuticals Co.) along with Tab Vitamin C (Batch 
No.6H03256, Mfg Date. Apr 2011, Square Pharmaceuticals Co.) 250mg daily, 
Tab Vitamin E (Batch No. 2916, Mfg Date. Jul 2011, Renata Pharmaceuticals 
Co.) 200 IU daily and Cap Vitamin A (Batch No.0619, Mfg Date. Feb 2011, 
Drug International Ltd.) 50000 IU twice weekly [11] and Group-B patients were 
given Tab. Methotrexate (Batch No.72E97044, Mfg Date. Aug 2011, Delta 
Pharmaceuticals Co.) 7.5mg/kg body weight/week to 25mg/kg body 
weight/week. All patients were given NSAIDS in the form of Naproxen 500 mg 
(Batch No.7703, Mfg Date. Mar 2011, Radiant Pharmaceuticals Co.) 12 hourly 
for 4 weeks and steroid in the form of Prednisolone 1 mg/Kg body weight for one 
month and then tapered. Then both groups were observed for the duration, 
frequency and severity of join pain, morning stiffness.  Side effects of the drugs 
like flu like illness, vomiting, diarrhea and constipation were recorded. 
Investigations like complete blood count, CRP, SGPT, Serum Creatitine, X-ray 
hand, RA factor with titre, Anti CCP were done. DAS 28 score was calculated 
by net calculator (DAS-28 has sensitivity of 87% and specificity of 67%). Base 
line findings were recorded at 1st visit (0 week), after giving the drugs different 
findings were recorded at 2nd visit (10th week). Antioxidants were stopped after 10 
weeks. Then the findings were again recorded at 3rd visit (14th week). Last 4 
weeks were the observation period without antioxidants. At the 10th week 7 
patients from Group A and 8 patients from Group B and at the  14th week  7 
patients of Group A and 6 patients  of  Group B  were dropped out.  
 
 
Data Processing and Analysis 
 
Data cleaning were done and data were entered into computer. Statistical 
analysis of the results being obtained by using windows based computer software 
device with SPSS -18(SPSS Inc, Chicago, IL, USA). All data were tested by 
using statistical methods-Chi-square test, t-test and ANOVA. Qualitative 
variables like age group, sex were analyzed by Chi-square test and quantitative 
variables like DAS 28, disease activities like changes in joint pain, swelling and 
tenderness, duration of morning stiffness, VAS score were analyzed by t-test and 
ANOVA. The statistical terms included in this study are mean, standard 
deviation and percentage. Statistical significance is set at p<0.05 and confidence 
interval set at 95% level.  
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Results 
 
Table I: Distribution of the age groups among the study groups (n=124):  
Age Group A 
(n=63) (%) 
Group B 
(n=61) (%) 
Total 
(n=124) (%) 
≤ 30 17(13.7%) 16(12.9%) 33(26.6%) 
30 – 40 24(19.4%) 10(8.1%) 34(27.4%) 
40 – 50 9(7.3%) 31(25.0%) 40(32.3%) 
50 – 60 6(4.8%) 2(1.6%) 8(17.7%) 
60+ 7(5.6%) 2(1.6%) 9(7.3%) 
Total 63(50.8%) 61(49.2%) 124(100.0%) 
Min= 22yrs, Max =70 yrs, Mean= 41.65 yrs, SD=11.04  
Χ2 value = 2.07  df = 4.  P = 0.08.  Not significant (P > 0.05) 
 
In group A, majority of patients were within 30-40 years (24, 19.4%), and in 
group B majority were within 40-50 years (31, 25.0%). Mean (±SD) age was 
41.65 ± 11.04 years the age difference between two groups were not significant 
(p>0.05). 
 
Table II: Clinical manifestation among the study groups (n=124): 
Features Group A (n=63)    Group B (n=61) 
Morning stiffness > 60 min  100.0% 100.0% 
Malaise 100.0% 100.0% 
Fever 15.9% 32.8% 
Weakness 100.0% 100.0% 
Weight Loss 47.6% 65.6% 
Muscle Wasting 31.7% 49.2% 
H/O multiple joint pain and swelling 100.0% 100.0% 
H/O generalized body ache with sleep disturbances 100.0% 100.0% 
Anaemia 82.5% 65.6% 
Vasculitis 4.8% 7.4% 
Tenosinovitis 10.7% 15.6% 
Bursitis 23.7% 29.2% 
Reynaud’s phenomenon 11.6% 12.8% 
Deformities 17.5% 19.2% 
 
Among the study patients morning stiffness, malaise, weakness, h/o multiple 
joint pain and swelling h/o generalized body ache and sleep disturbances were 
found in 100% of patients in both groups. Less common manifestations were 
fever, weight loss, anaemia, vasculitis, tenosinovitis etc found among the study 
groups. 
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Table III: Disease activity parameters in different visits 
Disease activity             Baseline  
            (Mean )   
1st visit (10th week) 
(Mean) 
2nd visit (14th week) 
(Mean) 
 Group A 
(n=63) 
Grou
p B 
(n=61
) 
Group A (n=56) Grou
p B 
(n=5
3) 
Group A 
(n=49) 
Group 
B 
(n=47) Number of tender joint  9.21 8.98 4.90 7.02 6.37 6.68 
Number of swollen joint 7.03 8.33 2.13 3.32 1.80 1.66 
Duration of fatigue in hours 4.71 5.11 2.40 3.17 1.87 3.17 
VAS [visual analogue score](0-10) 7.11 7.66 4.32 6.15 4.73 5.66 
DAS - 28 Score 6.1741 6.0656 4.4784 5.36
37 
4.8298 5.1020 
 
Among the study patients morning stiffness, malaise, weakness, h/o multiple 
joint pain and swelling h/o generalized bodyache and sleep disturbances were 
found in 100% of patients in both groups. Less common manifestations were 
fever, weight loss, anaemia, vasculitis, tenosinovitis etc found among the study 
groups. 
 
Table IV: Baseline disease activity among both groups: 
Disease activity Visit Group N Mean Std. 
Deviation 
Std. Error 
Mean 
Significance 
t P 
Number of tender joint 0 week Group A 63 9.21 2.772 .349    .591 .556 
Group B 61 8.98 1.008 .129 
Number of swollen joint 0 week Group A 63 7.03 4.068 .513 2.282 .024 
Group B 61 8.33 1.796 .230 
Duration of fatigue in hours 
 
0 week Group A 63 4.71 3.526 .444 .714 .477 
Group B 61 5.11 2.640 .338 
VAS* 
[visual analogue score] 
0 week Group A 63 7.11 1.357 .171 2.753 .007 
Group B 61 7.66 .750 .096 
DAS 28 Score** 
 
0 week Group A 63 6.1741 .71089 .08956 .934 .352 
Group B 61 6.0656 .57313 .07338 
 
Regarding analysis of different inflammatory parameters during first visit in 
group A and group B it was found that all parameters were comparable in both 
groups (p>0.05). 
 
 
 
Open Science Journal 
Research Article  
Open Science Journal – January 2018  9 
Table V: Disease activity among both groups at 2nd visit (10th week) 
Disease activity Visit Group N Mean Std. 
Deviation 
Std. Error 
Mean 
Significance 
t P 
Number of tender joint  10th 
week 
Group A 56 4.90 4.356 .553 3.635 .001 
Group B 53 7.02 1.008 .131 
Number of swollen joint 10th 
week 
Group A 56 .00 .000 .000 13.656 .001 
Group B 53 3.32 1.916 .249 
Duration of fatigue in 
hours   
 
10th 
week 
Group A 56 2.40 1.541 .196 2.780 .004 
Group B 53 3.17 1.487 .194 
VAS* 
[visual analogue score] 
10th 
week 
Group A 56 4.32 .954 .121 12.035 .001 
group B 53 6.15 .690 .090 
DAS 28 Score** 
 
10th 
week 
Group A 56 4.4784 1.10171 .13992 5.846 .001 
Group B 53 5.3637 .38230 .04977 
 
Regarding analysis of different inflammatory parameters during second visit in  
group A and group B, statistically significant change of  disease activities were 
found in both groups.(p<0.05), 
 
Table VI: Disease activity among both groups during 3rd visit (14th week) 
Disease activity Visit Group N Mean Std. 
Deviation 
Std. Error 
Mean 
Significance 
t P 
Joint pain/ tenderness 
(No of joint) 
14th week Group A 49 6.37 3.405 .440 0.677 0.50 
Group B 47 6.68 .955 .124 
Number of swollen joint 14th week Group A 49 1.80 3.052 .394 0.286 0.77 
Group B 47 1.66 2.170 .283 
Duration of fatigue in 
hours   
 
14th week Group A 49 1.87 1.096 .142 5.44 0.01 
Group B 47 3.17 1.487 .194 
VAS* 
[visual analogue score] 
14th week Group A 49 4.73 1.351 .174 4.61 0.01 
group B 47 5.66 .757 .099 
DAS 28 Score** 14th week Group A 49 4.829 .90822 .11725 2.05 0.04 
Group B 47 5.102 .46415 .06043 
 
Regarding analysis of different inflammatory parameters during third visit in 
group A and group B, statistically significant changes of  some disease activities 
were found in both (duration of fatigue, VAS, DAS28) groups (p<0.05)  but  not 
all(joint tenderness, number of swollen joints, p>0.05). 
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Follow up evaluation in Group A (methotraxate and 
antioxidant) patients:   
 
Disease activity in relation to joint pain and tenderness, joint swelling, 
duration of fatigue, VAS and DAS 28 score were found significantly different in 
follow up at 1st visit (difference between 0 and 10th week) and follow up at 2nd 
visit (difference between 10th and 14th week).  Findings at 1st visit and 2nd visit 
were found statistically significant (p<0.05). 
 
Table VIIa: Disease activity (Number of tender joints) in group A 
Number of tender joints N Mean Std. Deviation Std. Error Mean F p 
Baseline activity (0 week)  63 9.21 2.772 .349   
2nd visit (10th week) 56 4.258 3.146 .400 10.656 .001 
3rd visit (14th week) 49 1.433 1.522 .197 7.293 .001 
* ANOVA Test     
 
Table VIIb: Disease activity (Joint swelling) in group A 
Number of swollen joint N Mean Std. Deviation Std. Error Mean F p 
Baseline activity (0 week)    63 7.03 4.068 .513   
2nd visit (10th week) 56 7.000 4.093 .520 13.466 .001 
3rd visit (14th week) 49 1.800 3.052 .394 4.568 .001 
* ANOVA Test 
 
Table VIIc: Disease activity (Duration of fatigue) in group A 
Duration of fatigue (hours 
/day) 
N Mean Std. Deviation Std. Error Mean F P 
Baseline activity (0 week) 63 4.71 3.526 .444   
2nd visit (10th week) 56 2.194 2.023 .257 8.537 .001 
3rd visit (14th week) 49 .417 .696 .090 4.637 .001 
* ANOVA Test 
 
Table VIId: Disease activity (Visual analogue scale) in group A  
Visual analogue scale N Mean Std. Deviation Std. Error Mean F P 
Baseline activity (0 week) 63 7.11 1.357 .171   
2nd visit (10th week) 56 2.774 .895 .114 24.413 .001 
3rd visit (14th week) 49 .400 .694 .090 4.466 .001 
* ANOVA Test          
 
Table VIIe: Disease activity (DAS 28 score) in group A 
DAS 28 score N Mean Std. Deviation Std. Error 
Mean 
F P 
Baseline activity (0 week) 63 6.174 .710 .089   
2nd visit (10th week) 53 1.70 .509 .064 26.301 .001 
3rd visit (14th week) 47 .31 .388 .0501 6.353 .001 
* ANOVA Test 
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Follow up evaluation in Group B (Methotrexate only 
group) patients:   
 
Disease activity in relation with number of tender joint, number swollen joint, 
duration of fatigue in hour, VAS and DAS 28 score were analyzed. Statistically 
significant change of different parameters were found in follow up at 14th week in 
all activity markers (p>0.05) whereas it was found insignificant during follow-up 
at 10th week in reduction of tender joint, duration of fatigue and DAS 28 score 
(p>0.05). 
 
Table VIIIa: Disease activity (number of tender joints) in group B  
Number of tender Joint N Mean Std. Deviation Std. Error Mean F P 
Baseline activity (0 week)    61 8.98 1.008 .129   
2nd visit (10th week) 53 4.39 2.123 .310 3.223 .06 
3rd visit (14th week) 47 1.33 1.023 .184 4.321 .001 
       * ANOVA Test 
 
Table VIIIb: Disease activity (joint swelling) within group B 
Joint swelling (number)  N Mean Std. Deviation Std. Error Mean F P 
Baseline activity (0 week)    61 8.33 1.796 .230   
2nd visit (10th week) 53 6.10 5.193 .410 12.122 .007 
3rd visit (14th week) 47 1.321 1.052 .243 3.823 .001 
* ANOVA Test 
 
Table VIIIc: Disease activity (Duration of fatigue) within group B  
Duration of fatigue(hours 
/day) 
N Mean Std. Deviation Std. Error Mean F P 
Baseline activity (0 week)    61 5.11 2.640 .338   
2nd visit (10th week) 53 3.213 3.879 .732 8.437 .087 
3rd visit (14th week) 47 .354 .765 .082 3.761 .001 
* ANOVA Test 
 
Table VIIId: Disease activity (Visual analogue scale) within group B 
Visual analogue scale N Mean Std. Deviation Std. Error Mean F P 
Baseline activity (0 week)    61 7.66 .750 .096   
2nd visit (10th week) 53 4.987 .543 .324 22.336 .001 
3rd visit (14th week) 47 .634 .553 .230 3.554 .001 
* ANOVA Test 
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Table VIIIe: Disease activity (DAS 28 score) within group B 
DAS 28 score N Mean Std. Deviation Std. Error Mean F P 
Baseline activity (0 week)    61 6.065 .573 .073   
2nd visit (10th week) 53 2.50 .412 .043 3.301 .091 
3rd visit (14th week) 47 .42 .343 .0701 8.353 .001 
* ANOVA Test 
 
 
Side effect profile: Regarding side effect analysis hot flush was found 
common in Group A and other like anemia, oral ulcer, dyspepsia and diarrhea 
was found in both group A and B.   
 
Table IX: Side effect profile 
Side effects Group A 
(n=63) (%) 
Group B 
(n=61) (%) 
Total 
(n=124) (%) 
Hot flush 17(13.7%) 2(1.6%) 39(31.6%) 
Anemia  6(4.8%) 7(5.6%) 13(10.4%) 
Oral ulcer 9(7.3%) 6(4.6%) 15(12.03%) 
Dyspepsia 6(4.8%) 2(1.6%) 8(17.7%) 
Diarrhea 7(5.6%) 2(1.6%) 9(7.3%) 
Total 63(50.8%) 61(49.2%) 124(100.0%) 
 
 
Discussion 
 
There has been a great advance in the treatment of patients with RA. Now 
days many patients are interested in alternative treatment like dietary therapy. 
Although the etiology of RA is still unknown, the inflammation resulting from 
the immunological reaction is quite well described. It is known that neutrophil 
granulocytes, macrophages and lymphocytes are activated, so that reactive 
oxygen and nitrogen species (RS) are produced. These RS can react with lipid, 
protein and nucleic acids and are thought to be of importance for the etiology 
and chronicity of the inflammatory rheumatic diseases [8]. One approach to 
counteract this oxidative stress situation is the use of antioxidants as therapeutic 
agents. There is some evidence for a positive effect of antioxidants on clinical 
symptoms of RA [9]. However, this evidence is weak, and information about the 
most effective antioxidants, antioxidant doses or combinations are lacking. This 
intervention study has been tested vitamin E exclusively [10].  
In our study, a significant reduction in DAS, pain scale in the form of visual 
analogue score, number of tender and swollen joints was observed following 
antioxidant intervention on subsequent visits. Change of the disease activity 
markers were changed more in 14th than the earlier 0 week and 10th week in term 
of VAS, duration of fatigue, number of tender joints, number of swollen joints 
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and DAS 28 score (p<0.05). The reduction of DAS 28 was remarkable as all 
patients had an active (high initial mean DAS of 5.8) longstanding disease and 
had tried all kinds of disease-modifying anti-rheumatic drugs, including 
combination therapy. Concentration of antioxidant levels were not measured in 
our study. This finding were consistent with a study done before where 
antioxidant reduces the different disease activity score [10].  
Regarding analysis of different inflammatory parameters during first visit at 0 
week in group A and group B, were found that all parameters were comparable 
in both groups (p>0.05). But during 2nd visit at 10th week and 3rd visit at  14th 
week  were  found statistically significant regarding changes in  disease activities 
in  both groups (p<0.05).  A study done by Richard et al [11] where the 
potential beneficial effects of an antioxidant intervention on clinical parameters 
for RA were designed. Eight non-smoking female patients with rheumatoid factor 
+ RA and a Disease Activity Score (DAS 28) higher than 2.5 were enrolled in 
that study. They found the number of swollen and painful joints were 
significantly decreased and general health significantly increased, as reflected by 
a significantly improved (1.6) DAS at t = 10 weeks. The antioxidant effect was 
considered beneficial as compared to the scores at 0 week, the DAS significantly 
reduced after 10 weeks. Increase of the DAS (0.7) after the “wash-out period” at 
14th week confirmed a significant relation between changes in clinical condition 
and antioxidants. So the findings of the present study are consistent with their 
study. 
A limited number of clinical intervention studies are available which support 
the therapeutic or prophylactic activity of antioxidants in the treatment of RA. 
These studies were all conducted with an oral intake of 1,200 mg/day of vitamin 
E. reported that the antioxidant α-tocopherol significantly reduced pain 
parameters in a placebo-controlled double-blind trial following a 3-week 
supplementation period. Results from a randomized double-blind parallel group 
comparison study with a-tocopherol and diclofenac showed that the clinical 
parameters assessed, e.g. morning stiffness, Ritchie joint index, grip strength and 
pain, were significantly reduced by vitamin E, with similar effectivity and less 
side effects as compared to regular drug therapy by diclofenac. Results from 
other intervention studies have generally been in line with this observations [12].  
In our study, the effect of vitamin A, C and E on the inflammatory response 
and clinical symptoms were evaluated. In view of the limited number of 
controlled studies, the supporting evidence for beneficial effects of antioxidants 
on clinical characteristics of rheumatoid arthritis may be considered limited but 
promising. Another point is that the potential mechanism of action of 
antioxidants in rheumatoid arthritis needs further attention. The results indicate 
there may be potential benefit of using antioxidants Vitamins (A, C and E) in 
combination with methotrexate in the treatment of RA.  
 
 
Conclusion 
 
The use of antioxidant Vitamins (A, C and E) in combination with 
methotrexate in the treatment of RA is beneficial than that of methotrexate 
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alone. To clarify the effective dose of the Antioxidant Vitamins (A, C and E) to 
get effective result it is needed further study.  
 
 
Recommendation 
 
Large, double blind, randomized, placebo-controlled, multi centered trial are 
needed to establish effect of antioxidant vitamins in combination with 
methotrexate in the treatment RA. 
 
 
List of Abbreviations  
  
ARA: American Rheumatological Association CCP: Cyclical Citrullinated 
Peptide CRP:C -reactive protein, DAS:Disease activity  score, ESR:Erythrocyte 
sedimentation rate, PAD: Peptidyl Arginine Deaminase, RA: Rheumatoid 
arthritis, RF:Rheumatoid factor, SJC: Swollen joint count, TJC: Tender joint 
count VAS :Visual analogue scale    
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